CRL - Charles River Laboratories
185.77
| Index: | S&P 500 | P/E: | 22.94 | EPS (ttm): | 8.10 | Insider Own: | 1.08% | Shs Outstand: | 51.13M | Perf Week: | -2.46% |
| Market Cap: | 9.69B | Forward P/E: | 18.02 | EPS next Y: | 10.31 | Insider Trans: | -5.76% | Shs Float: | 50.59M | Perf Month: | -1.13% |
| Income(ttm): | 418.71M | PEG: | 7.99 | EPS next Q: | 2.54 | Inst Own: | 103.06% | Short Float: | 4.31% | Perf Quarter: | -8.83% |
| Revenue(ttm): | 4.06B | P/S: | 2.39 | EPS this Y: | -4.42% | Inst Trans: | -0.67% | Short Ratio: | 3.12 | Perf Half Y: | -11.47% |
| Book/sh: | 73.97 | P/B: | 2.51 | EPS next Y: | 1.06% | ROA: | 5.36% | Short Interest: | 2.18M | Perf Year: | -19.80% |
| Cash/sh: | 4.04 | P/C: | 46.03 | EPS next 5Y: | 2.87% | ROE: | 11.81% | 52W Range: | 176.48 - 275.00 | Perf YTD: | -21.42% |
| Dividend Est.: | - | P/FCF: | 17.29 | EPS past 5Y: | 14.84% | ROI: | 6.40% | 52W High: | -32.45% | Beta: | 1.39 |
| Dividend TTM: | - | Quick Ratio: | 1.14 | Sales past 5Y: | 12.89% | Gross Margin: | 32.70% | 52W Low: | 5.26% | ATR (14): | 6.78 |
| Dividend Ex-Date: | - | Current Ratio: | 1.48 | EPS Y/Y TTM: | -12.39% | Oper. Margin: | 15.05% | RSI (14): | 42.07 | Volatility: | 3.90% 3.12% |
| Employees: | 21800 | Debt/Eq: | 0.73 | Sales Y/Y TTM: | -3.67% | Profit Margin: | 10.31% | Recom: | 2.70 | Target Price: | 210.62 |
| Option/Short: | Yes / Yes | LT Debt/Eq: | 0.73 | EPS Q/Q: | -21.38% | Payout: | 0.00% | Rel Volume: | 1.61 | Prev Close: | 182.15 |
| Sales Surprise: | 3.46% | EPS Surprise: | 6.91% | Sales Q/Q: | -1.64% | Earnings: | Nov 06 BMO | Avg Volume: | 697.83K | Price: | 185.77 |
| SMA20: | -4.35% | SMA50: | -4.18% | SMA200: | -13.15% | Undervalued: 13.38% | Volume: | 1,122,931 | Change: | 1.99% | |
Graham Classic formula value: 103.57
(P/E=8 * 1g) Min value: 79.06
(current P/E * 2g) Max value: 208.6
Average value: 130.41
Charles River Laboratories International, Inc. engages in providing products and services to help pharmaceutical and biotechnology companies. It operates through the following segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. The RMS segment includes its insourcing solutions business and Charles River accelerator and development lab footprint. The DSA segment offers regulatory-required safety testing of potential new drugs, vaccines, industrial and agricultural chemicals, consumer products, veterinary medicines, and medical devices. The Manufacturing Solutions segment focuses on microbial solutions and biologics solutions. The company was founded by Henry L. Foster in 1947 and is headquartered in Wilmington, MA.
Attention! Trading on the stock market involves financial risks and is not suitable for everyone. The www.stocks-expert.com does not provide financial market trading services; it is for informational purposes only and is not responsible for the consequences of your trading decisions or the operation of the software. Before starting to trade in any markets, make sure you understand the risks associated with trading and that you have a sufficient level of training.